Telomir Pharmaceuticals, Inc. Increase (Decrease) in Prepaid Expense
Telomir Pharmaceuticals, Inc. (TELO) reported Increase (Decrease) in Prepaid Expense of $140.93 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2026-08-13
- Telomir Pharmaceuticals, Inc. increase (decrease) in prepaid expense for the quarter ending 2026-06-30 was -$33.41K.
- Telomir Pharmaceuticals, Inc. increase (decrease) in prepaid expense for the quarter ending 2026-03-31 was $174.34K, a 475.08% increase year-over-year.
- Telomir Pharmaceuticals, Inc. increase (decrease) in prepaid expense for the quarter ending 2025-12-31 was -$18.13K.
- Telomir Pharmaceuticals, Inc. increase (decrease) in prepaid expense for the quarter ending 2025-09-30 was -$2.47K.
- Telomir Pharmaceuticals, Inc. increase (decrease) in prepaid expense for fiscal 2025 was -$3.18K, a 105.57% decline from fiscal 2024.
- Telomir Pharmaceuticals, Inc. increase (decrease) in prepaid expense for fiscal 2024 was $57.16K, a 7916.83% increase from fiscal 2023.
- Telomir Pharmaceuticals, Inc. increase (decrease) in prepaid expense for fiscal 2023 was $713.00.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 6 month as first filed | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$33.41K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $140.93K 10-Q · filed 2026-08-13 | $122.80K derived: sum of 3 quarters · filed 2026-08-13 | $120.33K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $174.34K 10-Q · filed 2026-05-14 | $156.21K derived: sum of 2 quarters · filed 2026-05-14 | $153.74K derived: sum of 3 quarters · filed 2026-05-14 | $140.84K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | -$18.13K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$20.60K derived: sum of 2 quarters · filed 2026-03-17 | -$33.50K derived: sum of 3 quarters · filed 2026-08-13 | -$3.18K 10-K · filed 2026-03-17 | |
| 2025-09-30 | -$2.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$15.37K derived: sum of 2 quarters · filed 2026-08-13 | $14.95K 10-Q · filed 2025-11-10 | -$4.53K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | -$12.90K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $17.41K 10-Q · filed 2026-08-13 | $17.41K 10-Q · filed 2025-08-14 | -$2.06K derived: sum of 3 quarters · filed 2026-08-13 | -$12.53K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $30.32K 10-Q · filed 2026-05-14 | $10.84K derived: sum of 2 quarters · filed 2026-05-14 | $375.00 derived: sum of 3 quarters · filed 2026-05-14 | -$10.62K derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | -$19.47K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$29.94K derived: sum of 2 quarters · filed 2026-03-17 | -$40.94K derived: sum of 3 quarters · filed 2026-03-17 | $57.16K 10-K · filed 2026-03-17 | |
| 2024-09-30 | -$10.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$21.46K derived: sum of 2 quarters · filed 2025-11-10 | $76.63K 10-Q · filed 2025-11-10 | $76.38K derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | -$10.99K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $87.10K 10-Q · filed 2025-08-14 | $86.85K derived: sum of 3 quarters · filed 2025-08-14 | ||
| 2024-03-31 | $98.09K 10-Q · filed 2025-05-14 | $97.84K derived: sum of 2 quarters · filed 2025-05-14 | |||
| 2023-12-31 | -$250.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-04 | $713.00 10-K · filed 2025-02-04 | |||
| 2023-09-30 | $963.00 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |